ES2565080T3 - Formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol - Google Patents
Formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol Download PDFInfo
- Publication number
- ES2565080T3 ES2565080T3 ES09722681.5T ES09722681T ES2565080T3 ES 2565080 T3 ES2565080 T3 ES 2565080T3 ES 09722681 T ES09722681 T ES 09722681T ES 2565080 T3 ES2565080 T3 ES 2565080T3
- Authority
- ES
- Spain
- Prior art keywords
- polymorph
- oxadiazol
- nitrobenzene
- pyridin
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title 1
- ASOADIZOVZTJSR-UHFFFAOYSA-N opicapone Chemical compound CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C1=NOC(C=2C=C(C(O)=C(O)C=2)[N+]([O-])=O)=N1 ASOADIZOVZTJSR-UHFFFAOYSA-N 0.000 title 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005079 FT-Raman Methods 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6972108P | 2008-03-17 | 2008-03-17 | |
| US69721P | 2008-03-17 | ||
| PCT/PT2009/000013 WO2009116882A1 (en) | 2008-03-17 | 2009-03-16 | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2565080T3 true ES2565080T3 (es) | 2016-03-31 |
Family
ID=40585552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09722681.5T Active ES2565080T3 (es) | 2008-03-17 | 2009-03-16 | Formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8975410B2 (enExample) |
| EP (1) | EP2276758B1 (enExample) |
| JP (2) | JP2011514380A (enExample) |
| KR (1) | KR20110002462A (enExample) |
| CN (1) | CN102015696A (enExample) |
| AR (1) | AR070907A1 (enExample) |
| AU (1) | AU2009226221A1 (enExample) |
| BR (1) | BRPI0908731A2 (enExample) |
| CA (1) | CA2718772C (enExample) |
| CL (1) | CL2009000628A1 (enExample) |
| ES (1) | ES2565080T3 (enExample) |
| IL (1) | IL207854A0 (enExample) |
| MX (1) | MX2010009610A (enExample) |
| RU (1) | RU2010139315A (enExample) |
| TW (1) | TW200942531A (enExample) |
| WO (1) | WO2009116882A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1907382T1 (sl) | 2005-07-26 | 2015-10-30 | Bial-Portela & Ca S.A., | Nitrokateholni derivati kot inhibitorji COMT |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| ES2597705T3 (es) | 2007-01-31 | 2017-01-20 | Bial - Portela & Ca., S.A. | Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico |
| EP2276758B1 (en) | 2008-03-17 | 2016-01-06 | Bial-Portela & CA, S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol |
| PT2307020T (pt) * | 2008-07-29 | 2019-05-28 | Bial Portela & Ca Sa | Regime de administração de nitrocatecólicos |
| KR102329271B1 (ko) * | 2009-04-01 | 2021-11-22 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| AU2010231962B2 (en) * | 2009-04-01 | 2015-05-21 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
| US9848134B2 (en) | 2010-04-23 | 2017-12-19 | Flir Systems, Inc. | Infrared imager with integrated metal layers |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PL2791134T3 (pl) * | 2011-12-13 | 2020-03-31 | BIAL - PORTELA & Cª S.A. | Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| EP3298008B1 (en) * | 2015-05-20 | 2019-11-20 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| RU2659987C2 (ru) * | 2016-12-07 | 2018-07-04 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Планарный твердофазный оптический сенсор для определения белковых соединений методом спектроскопии гигантского комбинационного рассеяния и его применение для детектирования белковых соединений |
| JP2023517690A (ja) * | 2020-03-13 | 2023-04-26 | ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ | 微粉化オピカポン |
| GB202011709D0 (en) | 2020-07-28 | 2020-09-09 | Bial Portela & Ca Sa | Solid dispersion of opicapone |
| GB202016425D0 (en) | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| WO2022131944A1 (en) | 2020-12-17 | 2022-06-23 | Bial-Portela & Ca., S.A. | Treatment regimens for early idiopathic parkinson's disease |
| GB202219669D0 (en) | 2022-12-23 | 2023-02-08 | Bial Portela & Ca Sa | Processes and intermediates for synthesising opicapone |
| AU2023449890A1 (en) | 2023-05-25 | 2025-11-27 | Bial-Portela & Ca., S.A. | Treatment regimens for early idiopathic parkinson's disease |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1532178A (en) | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
| US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
| US5206372A (en) | 1990-06-05 | 1993-04-27 | Shell Research Limited | Preparation of 2-chloropyridine derivatives |
| DE69013689T2 (de) | 1990-11-29 | 1995-03-02 | Wei Ming Pharmaceutical Mfg Co | Hilfsträger für direkte Verpressung. |
| AU3171493A (en) | 1991-12-31 | 1993-07-28 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| FR2730322B1 (fr) | 1995-02-02 | 1997-04-30 | Imago | Monture de lunettes metallique |
| DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| US6206110B1 (en) | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| CA2337755C (en) | 1998-09-18 | 2008-07-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| IL131037A (en) | 1999-07-22 | 2004-06-20 | Israel Atomic Energy Comm | Method for making threedimensional photonic band-gap crystals |
| ATE307129T1 (de) | 1999-08-19 | 2005-11-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
| JP3965361B2 (ja) | 2000-08-24 | 2007-08-29 | 佐川急便株式会社 | 物流又は運送に関わるサービス料金のカード決済方法及びそのシステム |
| CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
| US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| CA2436739A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Combination agent |
| PL369598A1 (en) | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AU2002310187A1 (en) | 2001-05-30 | 2002-12-09 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| CN1638776A (zh) | 2001-06-08 | 2005-07-13 | 西托维亚公司 | 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物 |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| MXPA04000775A (es) | 2001-07-26 | 2004-04-20 | Merck Patent Ges Mit Baschrank | Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables. |
| JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
| EP1581213A4 (en) | 2002-12-18 | 2008-11-19 | Cytovia Inc | 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| AR045731A1 (es) | 2003-08-06 | 2005-11-09 | Vertex Pharma | Compuestos de aminotriazol utiles como inhibidores de quinasas de proteinas |
| US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EP1751133B1 (en) | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US20060173074A1 (en) | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
| WO2006061697A1 (en) | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
| WO2006071184A1 (en) | 2004-12-28 | 2006-07-06 | Astrazeneca Ab | Aryl sulphonamide modulators |
| US20080051441A1 (en) | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| JP2008539195A (ja) | 2005-04-26 | 2008-11-13 | ノイロサーチ アクティーゼルスカブ | 新規のオキサジアゾール誘導体及びそれらの医学的使用 |
| US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| US7553964B2 (en) | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
| US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
| SI1907382T1 (sl) | 2005-07-26 | 2015-10-30 | Bial-Portela & Ca S.A., | Nitrokateholni derivati kot inhibitorji COMT |
| FR2889525A1 (fr) | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
| US20070048384A1 (en) | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| EP1954137A4 (en) | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| US8022075B2 (en) | 2005-11-30 | 2011-09-20 | Fujifilm Ri Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| JP2008162955A (ja) | 2006-12-28 | 2008-07-17 | Chugai Pharmaceut Co Ltd | バリン含有高密度顆粒剤 |
| ES2597705T3 (es) | 2007-01-31 | 2017-01-20 | Bial - Portela & Ca., S.A. | Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico |
| PE20081891A1 (es) | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
| JP5718053B2 (ja) | 2007-08-27 | 2015-05-13 | ヘリコン・セラピューティクス・インコーポレーテッド | 治療用イソオキサゾール化合物 |
| EP2259777A2 (en) | 2008-02-28 | 2010-12-15 | BIAL - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| EP2276758B1 (en) | 2008-03-17 | 2016-01-06 | Bial-Portela & CA, S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol |
| PT2307020T (pt) | 2008-07-29 | 2019-05-28 | Bial Portela & Ca Sa | Regime de administração de nitrocatecólicos |
| US8827197B2 (en) | 2008-11-04 | 2014-09-09 | Microgreen Polymers Inc | Apparatus and method for interleaving polymeric roll for gas impregnation and solid-state foam processing |
| AU2010231962B2 (en) | 2009-04-01 | 2015-05-21 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
| KR102329271B1 (ko) | 2009-04-01 | 2021-11-22 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| WO2011107653A2 (en) | 2010-03-04 | 2011-09-09 | Orion Corporation | Method for treating parkinson's disease |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PL2791134T3 (pl) | 2011-12-13 | 2020-03-31 | BIAL - PORTELA & Cª S.A. | Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy |
-
2009
- 2009-03-16 EP EP09722681.5A patent/EP2276758B1/en active Active
- 2009-03-16 CN CN2009801099261A patent/CN102015696A/zh active Pending
- 2009-03-16 CL CL2009000628A patent/CL2009000628A1/es unknown
- 2009-03-16 US US12/933,044 patent/US8975410B2/en active Active
- 2009-03-16 ES ES09722681.5T patent/ES2565080T3/es active Active
- 2009-03-16 MX MX2010009610A patent/MX2010009610A/es not_active Application Discontinuation
- 2009-03-16 AU AU2009226221A patent/AU2009226221A1/en not_active Abandoned
- 2009-03-16 WO PCT/PT2009/000013 patent/WO2009116882A1/en not_active Ceased
- 2009-03-16 JP JP2011500722A patent/JP2011514380A/ja active Pending
- 2009-03-16 KR KR1020107022717A patent/KR20110002462A/ko not_active Withdrawn
- 2009-03-16 AR ARP090100933A patent/AR070907A1/es unknown
- 2009-03-16 TW TW098108415A patent/TW200942531A/zh unknown
- 2009-03-16 CA CA2718772A patent/CA2718772C/en active Active
- 2009-03-16 BR BRPI0908731A patent/BRPI0908731A2/pt not_active IP Right Cessation
- 2009-03-16 RU RU2010139315/04A patent/RU2010139315A/ru unknown
-
2010
- 2010-08-29 IL IL207854A patent/IL207854A0/en unknown
-
2014
- 2014-10-31 JP JP2014222625A patent/JP2015044837A/ja active Pending
-
2015
- 2015-02-23 US US14/628,630 patent/US9845316B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110002462A (ko) | 2011-01-07 |
| JP2011514380A (ja) | 2011-05-06 |
| MX2010009610A (es) | 2010-09-30 |
| EP2276758B1 (en) | 2016-01-06 |
| IL207854A0 (en) | 2010-12-30 |
| EP2276758A1 (en) | 2011-01-26 |
| US9845316B2 (en) | 2017-12-19 |
| CA2718772A1 (en) | 2009-09-24 |
| CA2718772C (en) | 2017-05-02 |
| AU2009226221A1 (en) | 2009-09-24 |
| TW200942531A (en) | 2009-10-16 |
| AR070907A1 (es) | 2010-05-12 |
| BRPI0908731A2 (pt) | 2017-05-16 |
| RU2010139315A (ru) | 2012-04-27 |
| JP2015044837A (ja) | 2015-03-12 |
| CN102015696A (zh) | 2011-04-13 |
| WO2009116882A1 (en) | 2009-09-24 |
| US20150166519A1 (en) | 2015-06-18 |
| US8975410B2 (en) | 2015-03-10 |
| US20110112301A1 (en) | 2011-05-12 |
| CL2009000628A1 (es) | 2010-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2565080T3 (es) | Formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol | |
| JP6924839B2 (ja) | 置換された多環性ピリドン誘導体の立体選択的な製造方法 | |
| TWI408135B (zh) | 腎外髓質鉀通道抑制劑 | |
| AR107173A2 (es) | Formas polimórficas e hidrato y sales de 6-{difluor[6-(1-metil-1h-pirazol-4-il)[1,2,4]triazolo[4,3-b]piridazin-3-il]metil}quinolina | |
| Hung et al. | Novel synthesis of 5-methyl-5, 10-dihydroindolo [3, 2-b] indoles by Pd-catalyzed C–C and two-fold C–N coupling reactions | |
| PE20140002A1 (es) | Proceso de elaboracion para derivados de pirimidina | |
| FI3978483T3 (fi) | (S)-afoksolaneerin kiteinen tolueenisolvaatti | |
| AU2015222584A1 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
| EA201201052A1 (ru) | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk | |
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| JP2013539765A5 (enExample) | ||
| WO2013102935A3 (en) | Cu-MEDIATED ANNULATION FOR THE EFFECTIVE SYNTHESIS OF 3-SUBSTITUTED PHTHALIDES | |
| AR078141A1 (es) | Modificacion cristalina de mesotriona, proceso de preparacion y composicion herbicida | |
| AR075418A1 (es) | Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad. | |
| RU2009141831A (ru) | Лечение мышечной дистрофии дюшенна | |
| AR052314A1 (es) | Compuestos de tienopiridinona como agonistas del receptor 5-ht4 | |
| RU2016134404A (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
| WO2013124748A4 (en) | Novel polymorphs of azilsartan medoxomil potassium | |
| US9708310B2 (en) | Phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof, preparation method and use thereof | |
| AR103209A1 (es) | Formas polimorficas del 4-metilbencil(3s,4r)-3-fluoro-4-[(pirimidin-2-ilamino)metil]piperidina-1-carboxilato | |
| RU2011143166A (ru) | Новые кристаллические формы адефовира дипивоксила и способы его получения | |
| Ibrahim et al. | Sequential staudinger ketene–imine cycloaddition, RCM approach to polycyclic macrocyclic bisazetidinones | |
| Choi et al. | Synthesis of 2-(4-hydroxyphenyl) benzofurans and their application to β-amyloid aggregation inhibitor | |
| Shumilova et al. | Synthesis of sulfonate derivatives of 4-heteryl-isoxazoles | |
| RU2017145927A (ru) | Кристаллический лиганд 6,6'-[[3,3',5,5'-тетракис(1,1-диметилэтил)-[1,1'-бифенил]-2,2'-диил]бис(окси)]бисдибензо[d,f][1,3,2]-диоксафосфепин |